BillionToOne, Inc.

The company is headquartered in the United States and generates the vast majority of its revenue domestically. Management says international markets represented less than 1% of revenue in 2025, and those markets are served mainly through distributors that send samples back to U.S. laboratories. The business therefore depends heavily on U.S. physician adoption, U.S. payor coverage, and U.S. laboratory operations. International expansion is a longer-term opportunity, but it likely requires local testing infrastructure and capital investment before meaningful scale can be achieved. Geography matters because reimbursement, sample logistics, and local testing requirements all shape how quickly the company can expand outside the U.S.

The company operates in a highly competitive molecular diagnostics market where established players can launch competing prenatal and carrier screening products. Its revenue is heavily dependent on a small number of test franchises, so any slowdown in UNITY adoption or a weaker competitive response could affect growth materially. Reimbursement risk is central because payment depends on third-party payors, claim approvals, and changing medical policies; adverse coverage decisions can delay cash collection or reduce realized pricing. The business is also exposed to execution risk from rapid growth, including hiring, systems, compliance, and customer service, which is especially important for a young company with a limited operating history. More generally, diagnostics companies face regulatory, intellectual property, data security, and laboratory operations risks, and BillionToOne’s use of sensitive patient data and patent-protected technology makes those issues particularly relevant.